Opinion|Videos|April 1, 2026
Navigating Second-Line Treatment Decisions in EGFR+ NSCLC
Author(s)Christine M. Lovly, MD, PhD, Matthew Lee, MD
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss second-line treatment approaches and sequencing considerations in EGFR-mutated non–small cell lung cancer.
Advertisement
Episodes in this series
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss evolving strategies for second-line treatment in EGFR-mutated non–small cell lung cancer. Lovly reviews how resistance mechanisms and prior therapy exposure guide treatment selection, including the use of targeted agents and antibody-drug conjugates. Lee underscores the importance of integrating emerging data from phase 3 trials such as MARIPOSA-2 (NCT04988295) and PALOMA-3 (NCT05388669) to refine sequencing decisions.
Advertisement
Related to this article
A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.
Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.
The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.
A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.
The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Advertisement
Advertisement
Trending on OncLive
1
RP1 Plus Nivolumab Preserves Quality-Adjusted Survival in Advanced Melanoma After Anti–PD-1 Therapy
2
Afami-Cel Outcomes Are Tied to MAGE-A4 Expression, Tumor Burden in Synovial Sarcoma
3
STX-001 Produces Durable Systemic Responses in PD-1–Resistant Melanoma
4
VET3-TGI Generates Responses in Checkpoint Inhibitor–Refractory Cutaneous Cancers
5